The team of scientists coordinated by Lyndon Emsley - who is currently Professor at EPFL and ENS Lyon - has developed a new generation of hyperpolarizing agents that are both effective and safe for the patient. The substances, called HYPSOs, were developed by the teams of Christophe Copéret at ETH Zurich and Chloé Thieuleux at CPE-Lyon. The HYPSOs come in the form of a fine, white, porous powder that contains the "tracking" molecules to be hyperpolarized. The HYPSO powder is made up of mesoporous silica (silicon dioxide), which is the major component of sand and is commonly used in nanotechnology.
The silica powder used for the HYPSOs consists of particles, containing pore channels. It has been designed in such a way that the surface of each pore channel can be evenly covered with molecules known as 'organic radicals'. The radicals are homogeneously distributed, and are able to induce polarization around them. "Controlling the radical distribution was a 'tour de force' never achieved in the past, which made the HYPSO materials ideal for this application," says Christophe Copéret. The pore channels are then filled with a solution of the "tracking" molecules to be hyperpolarized, which act as markers for the imaging - e.g. pyruvate, which is important in the production of energy in cells.
Using novel instruments and methods developed by Sami Jannin at EPFL, the HYPSO sample is hyperpolarized with microwaves in a magnetic field at a very low temperature. The magnetic moments of the atoms are forced to align through a process called "dynamic nuclear polarization", which transfers the spin energy of the free radicals' electrons to the markers' nuclei. The electronic spin magnetism of the hyperpolarizing agent acts on the marker molecule, aligning, or "polarizing", the nuclei of its atoms.
Hot water is then used to melt and flush the substrate out of the powder. Because of the equipment and conditions needed, the process generally takes place in a room adjacent to the imaging facility. The substrate is then ready to be injected through a long tube into the patient inside the medical imaging device. The entire process only lasts about ten seconds.
Two scans are performed, one with and one without the hyperpolarized agent. When the two images are compared, it is possible to observe the distribution of the hyperpolarized marker in the patient's body, which, depending on the medical context, can be indicative of disease. For example, accumulation of pyruvate in the prostate could be an early indication of prostate cancer.
The researchers have tested the efficiency of the HYPSOs method on several imaging markers, including pyruvate, acetate, fumarate, pure water, and a simple peptide. Because the HYPSOs is physically retained during dissolution, the technique yields pure solutions of hyperpolarized markers, free of any contaminant. The protocol is therefore simpler and potentially safer for the patient, while its dramatic efficiency on signal quality forecasts the use of this new generation of hyperpolarized agents with a broad range of molecules. As Sami Jannin points out: "We have now received queries of scientists from abroad who are eager to boost their research with this new technology. Amongst other plans, we are very excited about testing these materials in vivo."
This work represents a collaboration between EPFL, ENS Lyon, the Centre National de la Recherche Scientifique (CNRS), CPE Lyon, ETH Zurich, and the Swiss Commission for Technology and Innovation (CTI). It was also additionally funded by Lyon Science Transfert, the Swiss National Science Foundation, the SATT Lyon-Saint Etienne and the European Research Council.
Gajan D, Bornet A, Vuichoud B, Milani J, Melzi R, van Kalkeren HA, Veyre L, Thieuleux C, Conley MP, Grüning WR, Schwarzwälder M, Lesage A, Copéret C, Bodenhausen G, Emsley L, Jannin S. Hybrid polarizing solids for pure hyperpolarized liquids through dissolution dynamic nuclear polarization. PNAS 29 September 2014. DOI: 10.1073/pnas.1407730111